An update on medical management on Crohn’s disease

Bibliography

• Dignass A, Van Assche G, Linsday JO, et al.; for the European Crohn’s and Colitis Organisation (ECCO). The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohn’s Colitis 2010;4:28-62
   Google Scholar
• Lichtenstein GR, Hanauer SB, Sandborn WJ, et al. the; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn’s disease in adults. Am J Gastroenterol 2009;104:465
   PubMed Web of Science ®Google Scholar
• Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60(5):571-607
   PubMed Web of Science ®Google Scholar
• Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohn’s disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:617
   PubMed Web of Science ®Google Scholar
• Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease (Review). The Cochrane Collaboration Published by JohnWiley & Sons, Ltd; Cochrane Database Syst Rev. 2010 Dec 8;(12):CD008870; 2011
   Google Scholar
• Tromm A, Bunganič I, Tomsová E, et al. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn’s disease. Gastroenterology 2011;140:425
   PubMed Web of Science ®Google Scholar
• Arnold GL, Beaves MR, Pryjdun VO, et al. Preliminary study of ciprofloxacin in active Crohn’s disease. Inflamm Bowel Dis 2002;8:10-15
   PubMed Web of Science ®Google Scholar
• Ursing B, Alm T, Bàràny F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn’s disease: the cooperative Crohn’s disease study in Sweden. II. Result. Gastroenterology 1982;83(3):550-62
   PubMed Web of Science ®Google Scholar
• D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008;371:660
   PubMed Web of Science ®Google Scholar
• Ghazi LJ, Patil SA, Rustgi A, et al. Step up versus early biologic therapy for crohn’s disease in clinical practice. Inflamm Bowel Dis 2013;19:1397-403
   Google Scholar
• Summers RW, Switz DM, Sessions JTJr, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology 1979;77:847-69
   PubMed Web of Science ®Google Scholar
• Malchow H, Ewe K, Brandes JW. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66
   PubMed Web of Science ®Google Scholar
• Orlando A, Armuzzi A, Papi C, et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Clinical practice guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis 2011;43:1-20
   PubMedGoogle Scholar
• Sandborn WJ, Sutherland LR, Pearson D, et al. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’ s disease (Review). The Cochrane Collaboration Published by JohnWiley & Sons, Ltd; Cochrane Database Syst Rev. 2009;(4):CD000545; 2013
   Google Scholar
• McDonald JW, Tsoulis DJ, Macdonald JK, Feagan BG. Methotrexate for induction of remission in refractory Crohn’s disease. (Review). The Cochrane Collaboration Published by JohnWiley & Sons, Ltd; Cochrane Database Syst Rev. 2012 Dec 12;12:CD003459; 2012
   Google Scholar
• Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. and the AGA Institute Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute Guideline on the Use of Thiopurines, Methotrexate, and Anti–TNF-a Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn’s Disease. Gastroenterology 2013;145:1459-63
   PubMed Web of Science ®Google Scholar
• Bouhnik Y, Lémann M, Mary JY, et al. Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet 1996;347(8996):215-19
   PubMed Web of Science ®Google Scholar
• Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 2000;119:895-902
   PubMed Web of Science ®Google Scholar
• Cosnes J, Bourrier A, Laharie D, et al. Early administration of Azathioprine vs conventional management of Corhn’s disease: a randomized controlled trial. Gastroenterology 2013;145(4):758-65
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-53
   PubMed Web of Science ®Google Scholar
• Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease (Review). The Cochrane Collaboration Published by JohnWiley & Sons, Ltd; Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893; 2009
   Google Scholar
• Osterman MT, Haynes K, Delzell E, et al. Comparative effectiveness of infliximab and adalimumab for Crohn’s disease. Clin Gastroenterol Hepatol 2014;12:811-17
   PubMed Web of Science ®Google Scholar
• Kestens C, van Oijen MG, Mulder CL, et al. Adalimumab and infliximab are equally effective for Crohn’s disease in patients not previously treatedwith anti-tumor necrosis-factors alpha agents. Clin Gastroenterol Hepatol 2013;11:826-31
   PubMed Web of Science ®Google Scholar
• Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis 2013;72:517-24
   PubMed Web of Science ®Google Scholar
• Zhang D, Xiong B, Li X, et al. Meta-analysis: serious adverse events in Crohn’s disease patients treated with TNF-alpha inhibitors. Hepatogastroenterology 2013;60(126):1333-42
   PubMedGoogle Scholar
• Biancone L, Petruzziello C, Orlando A, et al. Cancer in Crohn’s disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis 2011;17:758-66
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012;107(7):1051-63
   PubMed Web of Science ®Google Scholar
• Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9(1):30-5
   PubMed Web of Science ®Google Scholar
• Danese S, Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease. J Crohns Colitis 2013;7(7):586-9
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fodorak RN, et al. Natalizumab for the Treatment of Active Crohn’s Disease: results of the ENCORE Trial. Gastroenterology 2007;132:1672-83
   PubMed Web of Science ®Google Scholar
• Juillerat P, Wasan SK, Fowler SA, et al. Efficacy and safety of natalizumab in Crohn’s disease patients treated at 6 Boston academic hospitals. Inflamm Bowel Dis 2013;19(11):2457-63
   PubMed Web of Science ®Google Scholar
• Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open label pilot study of low dose thalidomide in chronically active, steroid-dependend Crohn’s disease. Gastroenterology 1999;117(6):1278-87
   PubMed Web of Science ®Google Scholar
• Felipez LM, Gokhale R, Timey MP, et al. Thalidomide use and outcomes in patients with Crohn disease refractory to infliximab and adalimumab. J Pediatr Gastroenterol Nutr 2012;54(1):28-33
   PubMed Web of Science ®Google Scholar
• Zheng CF, Xu JH, Huang Y, Leung YK. Treatment of pediatric refractory Crohn’s disease with thalidomide. World J Gastroenterol 2011;17(10):1286-129
   Google Scholar
• Srinivasan R, Akobeng AK. Thalidomide and thalidomide analogues for induction of remission in Crohn’s disease (Review). The Cochrane Collaboration Published by JohnWiley & Sons, Ltd; Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007350
   Google Scholar
• Akobeng AK, Stokkers PC. Thalidomide and thalidomide analogues for maintenance of remission in Crohn’s disease (Review). The Cochrane Collaboration Published by JohnWiley & Sons, Ltd; Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351; 2009
   Google Scholar
• Lazzerini M, Martelossi S, Magazzù G, et al. Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial. JAMA 2013;310(20):2164-73
   PubMed Web of Science ®Google Scholar
• Schwartz DA, Loftus EV, Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology 2002;122:875-80
   PubMed Web of Science ®Google Scholar
• Tang LY, Rawsthorne P, Bernstein CN. Are perineal and luminal fistulas associated in crohn’s disease? A population-based study. Clin Gastroenterol Hepatol 2006;4:1130-4
   PubMed Web of Science ®Google Scholar
• Renna S, Orlando A, Cottone M. Trials in perianal crohn’s disease. Rev Recent Clin Trials 2012;7:297-302
   Google Scholar
• Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn’s disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2009;15:17-24
   PubMed Web of Science ®Google Scholar
• Maeda Y, Ng SC, Durdey P, et al. Randomized clinical trial of metronidazole ointment versus placebo in perianal Crohn’s disease. Br J Surg 2010;97:1340-7
   Google Scholar
• West RL, Van der Woude CJ, Hansen BE, et al. Clinical and endosonographic effect of ciprofloxacin on treatment of perianal fistulae in Crohn’s disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2004;20:1329-36
   PubMed Web of Science ®Google Scholar
• Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995;123:132-42
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology 2003;125:380-8
   PubMed Web of Science ®Google Scholar
• Hart AL, Plamondon S, Kamm MA. Topical tacrolimus in the treatment of perianal Crohn’s disease: exploratory randomized controlled trial. Inflamm Bowel Dis 2007;13:245-53
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340:1398-405
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350:876-85
   PubMed Web of Science ®Google Scholar
• Bouguen G, Siproudhis L, Gizard E, et al. Long-term outcome of perianal fistulising Crohn’s disease treated with infliximab. Clin Gastroenterol Hepatol 2013;11(8):975-8
   Google Scholar
• Hotokezaka M, Ikeda T, Uchiyama S, et al. Results of seton drainage and infliximab infusion for complex anal Crohn’s disease. Hepatogastroenterology 2011;58(109):1189-92
   Google Scholar
• Hukkinen M, Pakarinen MP, Piekkala M, et al. Treatment of complex perianal fistulas with seton and infliximab in adolescents with Crohn’s disease. J Crohn’s Colitis 2014;8(8):756-62
   Google Scholar
• Sciaudone G, Di Stazio C, Limongelli P, et al. Treatment of complex perianal fistulas in Crohn disease: infliximab, surgery or combined approach. Can J Surg 2010;53:299-304
   PubMed Web of Science ®Google Scholar
• Van der Hagen SJ, Baeten CG, Soeters PB, et al. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn’s disease: a preliminary report. Dis Colon Rectum 2005;48:758-67
   PubMedGoogle Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007;132:52-65
   PubMed Web of Science ®Google Scholar
• Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut 2009;58:940-8
   PubMed Web of Science ®Google Scholar
• Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: a randomized, double-blind, placebo controlled trial (ADAFI). Gut 2014;63(2):292-9
   PubMed Web of Science ®Google Scholar
• Schreiber S, Lawrance IC, Thomsen OØ, et al. Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease subgroup results from a placebo-controlled study. Aliment Pharmacol Ther 2011;33:185-93
   PubMed Web of Science ®Google Scholar
• Tonelli F, Giudici F, Asteria CR. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Cronh’s disease: a pilot study. Dis Colon Rectum 2012;55(8):870-5
   Google Scholar
• Poggioli G, Laureti S, Pierangeli F, et al. Local injection of adalimumab for perianal Crohn’s disease: better than infliximab? Inflamm Bowel Dis 2010;16:1631
   Google Scholar
• de la Pontilla F, Alba F, Garcia-Olmo D, et al. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/II a clinical trial. Int J Colorectal Dis 2013;28(3):313-23
   Google Scholar
• Kouklakis G, Efremidou EI, Zezos P. Adalimumab an effective and promising treatment for patients with fistulizing Crohn’s disease. J Med Case Rep 2011;5:109
   Google Scholar
• Sands BE, Blank MA, Patel K, et al. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004;2:912-20
   PubMed Web of Science ®Google Scholar
• de la Poza G, Lòpez-Sanroman A, Taxonera C, et al. Genital fistulas in female Crohn’s disease patients. Clinical characteristics and response to therapy. J Crohn’s Colitis 2012;6:276-80
   Google Scholar
• Papi C, Fasci Spurio F, Margagnoni G, et al. Randomized controlled trials in prevention of postsurgical recurrence in Crohn’s disease. Rev Recent Clin Trials 2012;7(4):307-13
   Google Scholar
• Ford AC, Khan KJ, Talley NJ, et al. 5-aminosalicylates prevent relapse of Crohn’s disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol 2011;106(3):413-20
   PubMed Web of Science ®Google Scholar
• Gordon M, Naidoo K, Thomas AG, et al. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease. Cochrane Database Syst Rev 2011(1):CD008414
   Google Scholar
• D’Haens GR, Vermeire S, van Assche G, et al. Therapy of metronidazole with Azathioprine to prevent postoperative recurrence of Crohn’s disease: a controlled randomized trial. Gastroenterology 2008;135:1123-9
   PubMed Web of Science ®Google Scholar
• Mañosa M, Cabré E, Bernal I, et al. Addition of metronidazole to azathioprine for the prevention of postoperative recurrence of Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Inflamm Bowel Dis 2013;19(9):1889-95
   PubMedGoogle Scholar
• Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in crohn ’ s disease: a meta-analysis. Am J Gastroenterol 2009;104:2089-96
   PubMed Web of Science ®Google Scholar
• Savarino E, Bodini G, Dulbecco P, et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn’s disease: a randomized controlled trial. Am J Gastroenterol 2013;108(11):1731-42
   PubMed Web of Science ®Google Scholar
• Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology 2009;136:441-50
   PubMed Web of Science ®Google Scholar
• Regueiro M, Kip KE, Baidoo L, et al. Postoperative Therapy With Infliximab Prevents Long-term Crohn’s Disease Recurrence. Clin Gastroenterol Hepatol 2014;12(9):1494-502
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for crohn’s disease. N Engl J Med 2013;369(8):711-21
   PubMed Web of Science ®Google Scholar
• Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with crohn’s disease in whom tumor necrosis factor antagonist treatment had failed. Gastroenterology 2014;147(3):618-27
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 2012;367:1519-28
   PubMed Web of Science ®Google Scholar
• Janssen Research and Development, LLC. A study to evaluate the safety and efficacy of ustekinumab in patients with moderately to severely active crohn’s disease who have failed or are intolerant to tumor necrosis factor (TNF) antagonist therapy (UNITI-1). Available from: http://clinicaltrials.gov/ct2/show/NCT01369329 NLM identifier: NCT01369329 [Accessed 6th March 2014]
   Google Scholar
• Janssen Research and Development, LLC. A study to evaluate the safety and efficacy of ustekinumab induction therapy in patients with moderately to severely active crohn’s disease (UNITI-2). Available from: http://clinicaltrials.gov/ct2/show/NCT01369342 NLM identifier: NCT01369342 [Accessed 6th March 2014]
   Google Scholar
• Janssen Research and Development, LLC. A study to evaluate the safety and efficacy of ustekinumab maintenance therapy in patients with moderately to severely active crohn’s disease (IM-UNITI). Available from: http://clinicaltrials.gov/ct2/show/NCT01369355 NLM identifier: NCT01369355 [Accessed 6th March 2014]
   Google Scholar
• Badat Y, Meissner WG, Laharie D. Demyelination in a patient receiving ustekinumab for refractory Crohn’s disease. J Crohn Colitis 2014;8(9):1138-9
   PubMed Web of Science ®Google Scholar
• Monteleone G, Fantini MC, Onali S, et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn’s disease. Mol Ther 2012;20:870-6
   PubMed Web of Science ®Google Scholar
• Oyama Y, Craig RM, Traynor AE, et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn’s disease. Gastroenterology 2005;128(3):552-63
   PubMed Web of Science ®Google Scholar
• Burt RK, Craig RM, Milanetti F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood 2010;116(26):6123-32
   PubMed Web of Science ®Google Scholar
• Duijvestein M, Vos AC, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: results of a phase I study. Gut 2010;59(12):1662-9
   PubMed Web of Science ®Google Scholar
• Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012;61(11):1619-35
   PubMed Web of Science ®Google Scholar
• Walsh A, Palmer R, Travis S. Mucosal healing as a target therapy for colonic inflammatory bowel disease and methods to score disease activity. Gastrointest Endosc Clin N Am 2014;24(3):367-78
   PubMedGoogle Scholar
• Rutgeerts P, Assche GV, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology 2012;142:1102-11
   PubMed Web of Science ®Google Scholar
• Su C, Lichtenstein GR, Krok K, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn’s disease. Gastroenterology 2004;126:1257-69
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Vavricka S, Zahnd-straumann N, et al. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. J Crohns Colitis 2012;6(4):412-18
   PubMedGoogle Scholar
• Bouguen G, Levesque BG, Feagan BG, et al. Treat to target: a proposed new paradigm for the management of crohn’s disease. Clin Gastroenterol Heopatol 2013. [ Epub ahead of print]
   Google Scholar
• Kim MJ, Lee JS, Lee JH, et al. Infliximab therapy in children with Crohn’s disease: a one-year evaluation of efficacy comparing ’top-down’ and ’step-up’ strategies. Acta Paediatr 2011;100(3):451-5
   Google Scholar
• Walters TD, Kim M, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-alpha vs an immunomodulator in children with crohn’s disease. Gastroenterology 2014;146:383-91
   PubMed Web of Science ®Google Scholar
• Lee YS, Baek SH, Kim MJ, et al. Efficacy of early infliximab treatment for pediatric crohn’s disease: a three-year follow-up. Pediatr Gastroenterol Hepatol Nutr 2012;15(4):243-9
   PubMedGoogle Scholar
• Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohn’s Colitis 2014;8(10):1179-207
   Google Scholar
• Vernier–Massouille G, Balde M, Salleron J, et al. Natural history of pediatric crohn’s disease: a population-based cohort study. Gastroenterology 2008;135:1106-13
   PubMed Web of Science ®Google Scholar
• Schreiber S, Reinisch W, Colombel JF, et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn’s disease. J Crohn’s Colitis 2013;7:213-21
   Google Scholar
• Abraham NS, Richardson P, Castillo D, Kane SV. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11(10):1281-7
   Google Scholar
• Jones DW, Finlayson SR. Trends in surgery for Crohn’s disease in the era of infliximab. Ann Surg 2010;252:307-12
   PubMed Web of Science ®Google Scholar
• Lémann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Cronhn’s disease patients: a randomized placebo-controlled trial. Gastroenterology 2006;130(4):1054-61
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362(15):1383-95
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut 2009;58(4):492-500
   PubMed Web of Science ®Google Scholar
• Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008;134(7):1861-8
   PubMed Web of Science ®Google Scholar
• Van de Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013;108(6):962-71
   Google Scholar
• Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9(1):36-41
   PubMed Web of Science ®Google Scholar
• Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut 2014;63(9):1381-92
   PubMed Web of Science ®Google Scholar